BioCardia (BCDA) announced completion of enrollment and dosing in the low dose cohort in its CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial. The trial is designed to treat patients with ischemic heart failure of reduced ejection fraction, HFrEF, and is believed to be the world’s first prospective trial of allogeneic mesenchymal stem cells, MSC, intended for treating HFrEF patients having elevated markers of heart stress and systemic inflammation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCDA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue